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Abstract
Background: Agmatine is an endogenous polyamine formed by the decarboxylation of L-arginine.
We investigated the protective effects of agmatine against hypoxia-induced apoptosis of
immortalized rat retinal ganglion cells (RGC-5). RGC-5 cells were cultured in a closed hypoxic
chamber (5% O2) with or without agmatine. Cell viability was determined by lactate dehydrogenase
(LDH) assay and apoptosis was examined by annexin V and caspase-3 assays. Expression and
phosphorylation of mitogen-activated protein kinases (MAPKs; JNK, ERK p44/42, and p38) and
nuclear factor-kappa B (NF-κB) were investigated by Western immunoblot analysis. The effects of
agmatine were compared to those of brain-derived neurotrophic factor (BDNF), a well-known
protective neurotrophin for retinal ganglion cells.
Results: After 48 hours of hypoxic culture, the LDH assay showed 52.3% cell loss, which was
reduced to 25.6% and 30.1% when agmatine and BDNF were administered, respectively. This
observed cell loss was due to apoptotic cell death, as established by annexin V and caspase-3 assays.
Although total expression of MAPKs and NF-κB was not influenced by hypoxic injury,
phosphorylation of these two proteins was increased. Agmatine reduced phosphorylation of JNK
and NF-κB, while BDNF suppressed phosphorylation of ERK and p38.
Conclusion: Our results show that agmatine has neuroprotective effects against hypoxia-induced
retinal ganglion cell damage in RGC-5 cells and that its effects may act through the JNK and NF-κB
signaling pathways. Our data suggest that agmatine may lead to a novel therapeutic strategy to
reduce retinal ganglion cell injury related to hypoxia.
Background
Agmatine is an endogenous polyamine that is synthesized
by the decarboxylation of L-arginine by arginine decar-
boxylase [1,2]. It is known to be widely but unevenly dis-
tributed in the brain and other mammalian tissues [3,4].
Agmatine has been reported to have various biological
actions. It stimulates the release of catecholamines from
adrenal chromaffin cells [3], insulin from pancreatic islets
[5], and luteinizing hormone-releasing hormone from the
hypothalamus [6]. Also, it enhances analgesic effects of
morphine [7], inhibits inducible nitric oxide synthase
(NOS) [8], and contributes to polyamine homeostasis
[2,9]. It is known that agmatine is an agonist for α2-adren-
ergic and imidazoline receptors [3], and an antagonist for
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ever, the precise cellular mechanisms by which agmatine
acts are not yet well established.
Currently, a large body of experimental evidence has dem-
onstrated the neuroprotective effects of agmatine. Agma-
tine reduces infarct areas and neuronal loss in cerebral
ischemic and ischemic-reperfusion injury models [11-13].
It protects neurons from cell death after exposure to
NMDA and glutamate [14,15]. It also attenuates the
extent of neuronal loss following a spinal cord injury
[16,17] and shelters neurons from glucocorticoid-induced
neurotoxicity [18] and 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine-related dopaminergic toxicity [19].
On the basis of these neuroprotective effects, agmatine
can be presumed to have similar neuroprotective effects
on retinal ganglion cells (RGCs). Several molecules,
including α2-adrenergic agonists [20-25], NMDA receptor
antagonists [26-28] and NOS inhibitors [29], have been
reported to protect RGCs. Agmatine also acts as an α2-
adrenergic agonist [3], NMDA receptor antagonist [10],
and suppressor of inducible NOS [8].
In the present investigation, we examined the protective
effects of agmatine on hypoxia-induced apoptosis of
RGCs by using the transformed rat RGCs (RGC-5 cell line)
[30-32]. Effects of agmatine were compared to those of
brain-derived neurotrophic factor (BDNF), a well-known
protective neurotrophin for RGCs [33-35]. In addition,
several molecular pathways associated with these neuro-
protective effects of agmatine were evaluated.
Results
Agmatine inhibits hypoxia-induced cell damage of RGC-5 
cells
We first examined the effects of hypoxia on RGC-5 cells.
As shown in Figure 1, exposure to a hypoxic environment
for 12, 24, and 48 hours significantly increased release of
lactate dehydrogenase (LDH) by 10.17%, 20.04%, and
52.25%, respectively (all p < 0.001), thus demonstrating
time-dependent hypoxia-induced neurotoxicity.
Next, we examined the protective effects of agmatine on
hypoxia-induced damage in RGC-5 cells. After 12 and 24
hours of hypoxia, agmatine treatment groups did not
show significant amounts of LDH release (Fig. 1A and
1B), but there were significant effects after 48 hours of
exposure (Fig. 1C). After 48 hours, the addition of 100 μM
and 500 μM agmatine decreased hypoxia-induced LDH
release by 25.60% and 27.09%, respectively (both p <
0.001). When the protective effects of 100 μM agmatine
were compared with those of 10 ng/mL BDNF, agmatine
demonstrated a more powerful protective effect than that
observed for BDNF (p < 0.001).
The neuroprotective effect of agmatine against hypoxia-
induced damage to RGC-5 cells was further studied using
Hoechst 33342 and propidium iodide (PI) double stain-
ing. The control normoxic culture exhibited confluent
Hoechst-positive cells with homogeneous and compact
nuclear morphology, and sparse numbers of PI-labeled
cells (Fig. 2A). Exposure to hypoxia for 48 hours resulted
in a significant loss of Hoechst-positive cells and many PI-
positive cells with distorted and condensed nuclei (Fig.
2B). These changes were reduced by the addition of 100
μM agmatine (Fig. 2C) or 10 ng/mL BDNF (Fig. 2D) to the
cultures, and agmatine had a greater protective effect.
Agmatine protects RGC-5 cells from hypoxia-induced 
apoptosis
In order to verify whether agmatine had protective effects
on hypoxia-induced apoptotic death of RGC-5 cells, fur-
ther analyses using annexin V assay were performed.
While 12 hours of hypoxic exposure did not change the
proportion of apoptotic cells compared with the nor-
moxic culture, there were significant increases in apop-
totic cells after 24 hours (Fig. 3B). With the addition of
100 μM agmatine and 10 ng/mL BDNF, the proportion of
apoptotic cells decreased (Fig. 3C and 3D).
Specific caspase-3 activity was assessed using a caspase-3
assay, which could measure the cleavage of the caspase-3
specific substrate Ac-DEVD-pNA (Fig. 4). After 24 hours of
hypoxic injury, the caspase-3 activity was significantly
increased, and it was suppressed by 100 μM agmatine. The
results obtained by adding 100 μM agmatine were similar
to those seen with 50 μM caspase-3 inhibitor Z-VAD-FMK.
Selective suppression of JNK activation by agmatine
Three mitogen-activated protein kinases (MAPKs), includ-
ing c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase, (ERK) and p38 kinase (p38), were inves-
tigated using Western immunoblots. The amounts of total
and phosphorylated MAPKs and β-actin are shown in Fig-
ure 5.
Total expression of the three MAPKs (JNK, ERK, and p38)
and β-actin were not affected by hypoxic injury. In addi-
tion, there were no significant changes after treatment
with BDNF or agmatine.
Antibodies against phospho-JNKs detected two bands at
54 and 46 kDa, and both bands had a similar tendency.
Increases of phospho-JNKs in RGC-5 cells became evident
9 hours after hypoxic injury and remained elevated for 12
hours (Fig. 5A). Agmatine suppressed the hypoxia-
induced phosphorylation of JNKs, but BDNF did not
influence their phosphorylation.Page 2 of 11
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LDH release in RGC-5 cellsFigure 1
LDH release in RGC-5 cells. LDH release in RGC-5 cells, illustrating the neuroprotective effects of agmatine and BDNF 
against hypoxia for (A) 12 hours, (B) 24 hours, and (C) 48 hours. Data are shown as mean ± S.E.M. of 32 measurements. *P < 
0.001.
BMC Neuroscience 2007, 8:81 http://www.biomedcentral.com/1471-2202/8/81Antibodies against phospho-ERKs also detected two
bands at 44 and 42 kDa, and both bands were similar.
Phospho-ERKs were not detected in the normoxic cul-
tures. However, they were highly expressed in RGC-5 cells
even after 3 hours of hypoxia and remained elevated for
12 hours (Fig. 5B). BDNF completely blocked the phos-
phorylation of ERKs for 6 hours, but it had no effect there-
after. In comparison, agmatine did not significantly affect
the phosphorylation of ERKs.
Antibodies against phospho-p38 detected one band at 38
kDa. Phospho-p38 was not detected in normoxic cultures
until 12 hours of exposure to hypoxia, but it was evident
in hypoxic cultures even after 3 hours and remained ele-
vated for 12 hours (Fig. 5C). BDNF only blocked the
phosphorylation of p38 at 6 hours and agmatine had no
effect on phospho-p38 levels at any time points.
Thus, phospho-MAPKs showed different activation pro-
files in response to hypoxic injuries in RGC-5 cells; ERK
and p38 were activated relatively earlier than JNK. BDNF
inhibited the activation of ERK (until 6 hours after
hypoxia) and p38 (at 6 hours after hypoxia), while agma-
tine suppressed the activation of JNK (in significant
amounts from 9 hours after hypoxia).
Suppression of NF-κB signaling by agmatine
Total expression and activation of the nuclear factor-
kappa B (NF-κB) from nuclear and cytosolic fractions
were evaluated separately. Representative bands from the
Hoechst 33342 and propidium iodide double staining in RGC-5 cellsFigure 2
Hoechst 33342 and propidium iodide double staining in RGC-5 cells. Agmatine and BDNF reduce the hypoxia-
induced cell death in RGC-5. RGC-5 cells were exposed to hypoxia for 48 hours either alone (B) or in the presence of 100 μM 
agmatine (C) or 10 ng/mL BDNF (D). A control normoxic culture is shown in (A). The cultures were stained with Hoechst 
33342 and propidium iodide. The magnification is × 400.Page 4 of 11
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against total and phospho-NF-κB bound to their respec-
tive bands at 65 kDa.
In nuclear fraction, total NF-κB and histone 3 were unaf-
fected by hypoxic injury, and there were no changes with
the addition of BDNF and agmatine. However, phospho-
NF-κB was significantly increased with 1 hour of hypoxia
and returned to normal levels after 3 hours. This increase
in phospho-NF-κB was suppressed by agmatine but not
by BDNF (Fig. 6A).
In comparison, in cytoplasmic fraction, there were no sig-
nificant changes in levels of phospho-NF-κB and β-actin.
However, total NF-κB expression increased after 1 hour
exposure to a hypoxic environment. This increase was
reduced by treatment with agmatine but not BDNF (Fig.
6B).
Discussion
Our present study demonstrates that agmatine, an endog-
enous polyamine with a guanidino group, prevents
hypoxia-induced LDH release and apoptotic death in cul-
tured transformed rat RGCs (RGC-5 cell line). Release of
LDH was detected by LDH assay and the proportions of
apoptotic cells were determined by annexin V and cas-
pase-3 assays. Although agmatine cannot completely
block cellular damage due to hypoxic injury, it has similar
Annexin V assay in RGC-5 cellsFigure 3
Annexin V assay in RGC-5 cells. Flow cytometric analysis of effects of agmatine and BDNF on the hypoxia-induced apopto-
sis of RGC-5 cells. Cells were exposed to hypoxia for 24 hours either alone (B) or in the presence of 100 μM agmatine (C) or 
10 ng/mL BDNF (D). A control normoxic culture is shown in (A). Cultures were stained with annexin V-FITC and propidium 
iodide. Cells of high reactivity with FITC and low reactivity with propidium iodide (right lower area) are the apoptotic cells.Page 5 of 11
(page number not for citation purposes)
BMC Neuroscience 2007, 8:81 http://www.biomedcentral.com/1471-2202/8/81and even more extensive neuroprotective effects than
BDNF, a well-known protective neurotrophin for RGCs
[33-35]. Many molecules have been studied to rescue
RGCs from glaucomatous cell death [20-29,33-35], but
there is still no drug which completely shelters RGCs from
injury.
In this study, undifferentiated RGC-5 cells were used
instead of differentiated RGC-5 cells or primary RGCs.
These immortalized cells behave differently than original
RGCs, and our in vitro hypoxic model does not perfectly
replicate in vivo conditions that lead to real glaucomatous
injury. However, RGC-5 cells, even if they are undifferen-
tiated, have been widely used to investigate glaucomatous
RGC apoptosis as a matter of convenience [36-43]. It has
been often stated that RGC-5 cells have similar character-
istics to primary RGCs [30-32,44,45]. The present study
using RGC-5 cells suggests a solution to the problem,
although further investigations using primary cultured
RGCs or in vivo glaucoma models are needed.
Various functions of agmatine have been reported [3-10],
but the precise cellular mechanisms of agmatine are not
well established. In the present study, three types of
MAPKs and NF-κB signaling pathways were evaluated.
With hypoxic injury, phosphorylation of all three MAPKs
and NF-κB were increased. Agmatine suppressed the
hypoxia-induced activation of JNK and NF-κB, whereas
BDNF inhibited the activation of ERK and p38. These dif-
ferences might be caused by different mechanisms of
action of the two molecules.
MAPKs are involved in highly conserved signaling path-
ways that regulate diverse cellular functions including cell
proliferation, differentiation, migration, and apoptosis
[46-48]. They are activated through phosphorylation by
distinct pathways depending on stimulus and cell type.
When activated, they can phosphorylate a wide range of
substrates, including transcription factors and cytoskeletal
proteins, resulting in specific cellular responses. In the
present study, agmatine regulated the activation of JNK,
but not ERK and p38, in RGC-5 cells after hypoxic injury.
Our results are discrepant with those of a previous report
using kidney mesangial cells under high-glucose condi-
tions, in which agmatine was involved in the ERK path-
way [49]. However, there are no reports about agmatine's
effects on MAPKs in the literature, and MAPKs have been
known to work differently depending on stimuli and cell
types. Furthermore, due to the implications of a report
demonstrating that another antagonist of the NMDA
receptor MK801 can block the phosphorylation of MAPKs
[50], agmatine's actions as an antagonist for the NMDA
receptor [10] suggest that it might also regulate the phos-
phorylation of MAPKs.
In the present study, we revealed that there was an activa-
tion of NF-κB in RGC-5 cells after hypoxic injury, and
agmatine was able to suppress it. Our results are consist-
ent with previous reports that suggest that NF-κB is acti-
vated during oxidative stress [51-54]. However, Charles et
al. [44] obtained a discrepant result in which the activity
of NF-κB was decreased with serum-deprivation-induced
apoptosis. While oxidative stress models, including our
own hypoxic model, are based on the vascular theory of
glaucoma development, the serum deprivation model is
based on the mechanical pressure theory [55]. NF-κB sig-
naling is presumed to have various responses according to
the type of injury.
Perhaps the most significant finding in this study was that
both the increases in annexin V-positive cell number and
caspase-3 activity produced by exposure of RGC-5 cells to
hypoxia were counteracted by the addition of agmatine
into the culture medium. This suggests that agmatine may
exert a neuroprotective effect by inhibiting apoptosis in
the hypoxia-injured RGC-5 cells. To our knowledge, this is
the first report regarding the potential anti-apoptotic char-
acteristics of agmatine in RGCs.
Even though this study demonstrates that activations of
JNK and NF-κB were associated with the agmatine treat-
ment, it is still not certain whether there is a close connec-
tion between neuroprotective effects of agmatine and
signaling of JNK and NF-κB. However, it is presumed that
Caspase-3 assay in RGC-5 cellsFigure 4
Caspase-3 assay in RGC-5 cells. Colorimetric analysis of 
the effects of agmatine on the caspase-3 activity induced by 
hypoxic injury in RGC-5 cells. Cells were exposed to hypoxia 
for 24 hours with or without 100 μM agmatine or caspase-3 
inhibitor Z-VAD-FMK (50 μM). Specific activity of caspase-3 
was measured by cleavage of the caspase-3 substrate Ac-
DEVD-pNA.Page 6 of 11
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regulate JNK and NF-κB pathways may contribute to pro-
tecting RGCs against hypoxia-induced cell death. Further
studies are needed to elucidate the precise mechanisms by
which agmatine blocks apoptosis. A deeper understand-
ing of these mechanisms may facilitate efforts to improve
the survival of RGCs from various injuries.
Conclusion
Agmatine prevents hypoxia-induced LDH release and
apoptotic death in transformed RGCs (RGC-5 cells).
These neuroprotective effects of agmatine might be asso-
ciated with the activity of JNK and NF-κB pathways.
Methods
Chemicals and antibodies
Agmatine sulfate and recombinant human BDNF were
purchased from Sigma (St. Louis, MO) and R&D System,
Inc. (Minneapolis, MN), respectively. Rabbit polyclonal
anti-JNK p54/46, anti-ERK p44/42, anti-p38, anti-NF-κB
p65, anti-phospho-JNK p54/46, anti-phospho-ERK p44/
42, anti-phospho-p38, anti-phospho-NF-κB p65, and
anti-histone 3 antibodies were purchased from Cell Sign-
aling Technology, Inc (Danvers, MA). Mouse monoclonal
anti-β-actin antibody was purchased from Santa Cruz Bio-
technology, Inc (Santa Cruz, CA).
Cell culture
RGC-5 cell line [30-32], a transformed RGCs developed
from post-natal Sprague-Dawley rats, was grown in mod-
ified Dulbecco's modified Eagle's medium (DMEM;
Gibco, Carlsbad, CA) supplemented with 10% heat-inac-
tivated fetal bovine serum (Gibco, Carlsbad, CA) and 100
U/mL of penicillin and 100 μg/mL of streptomycin
(Gibco, Carlsbad, CA). Cells were passaged every 2 to 3
days, and the cultures incubated at 37°C in 5% CO2 and
Western blot analysis of MAPKs in RGC-5 cellsFigure 5
Western blot analysis of MAPKs in RGC-5 cells. Western blot analysis showing effects of agmatine and BDNF on 
mitogen-activated protein kinases (MAPKs). Western immunoblots probed with antibodies against JNK and phospho-JNK (A), 
ERK and phospho-ERK (B), p38 and phospho-p38 (C), and β-actin (D).Page 7 of 11
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logical phenotype. For all experiments, cells were used at
an 80% confluence.
Hypoxic injury to retinal ganglion cells
Cultures were transferred into a closed hypoxic chamber
(Forma Scientific Co., Seoul, Korea) in which oxygen level
(5% O2, 5% CO2, 90% N2) and temperature (37°C) were
automatically controlled. After washing twice with deoxy-
genated serum-free DMEM, cells remained in the hypoxic
chamber for the designated lengths of time. Control cells
were not exposed to hypoxia. Agmatine or BDNF were
added to the culture medium at the start of injury as indi-
cated.
Lactate dehydrogenase assay
Cell viability was quantified by measurement of LDH
released by injured cells after hypoxic or normoxic culture
for 12, 24, and 48 hours [56,57]. LDH release is expressed
relative to the value of 100, which represented the maxi-
mum LDH release that occurred after freezing overnight at
-70°C and subsequent rapid thawing of each culture,
which induced nearly complete cell damage. All experi-
ments were performed in at least quadruplicate and
repeated at least eight times using cell cultures derived
from different platings. Preliminary studies with the LDH
assay tested agmatine concentrations from 10 μM to 1
mM and BDNF concentrations ranging from 5 ng/mL to
100 ng/mL. Cell death was reduced significantly at 100
μM and greater concentrations of agmatine and 10 ng/mL
and greater concentrations of BDNF, so we used 100 μM
agmatine and 10 ng/mL BDNF for subsequent experi-
ments.
Hoechst 33342 and propidium iodide staining
Apoptotic or necrotic cell death was characterized by the
use of Hoechst 33342 and PI double staining [58,59].
Cells were stained with 10 μg/mL Hoechst 33342 and 10
μg/mL PI for 30 min at 37°C. After washing twice with
phosphate buffered saline, cells were imaged with a dig-
ital camera attached to a fluorescence microscope.
Annexin V assay
Percentage of cells actively undergoing apoptosis was
determined by flow cytometry using the Annexin V-FITC
Apoptosis Detection Kit (BD Biosciences, San Jose, CA)
according to the manufacturer's instructions. Briefly, cells
were harvested and resuspended in binding buffer (106
cells/mL). 105 cells were mixed with 5 μL of annexin V-
FITC and 5 μL of PI. After incubating at room temperature
for 15 minutes in the dark, analysis was performed by
flow cytometry.
Measurement of Caspase-3 activity
Caspase-3 activity was measured using the CaspACETM
colorimetric assay system (Promega, Madison, WI)
according to the manufacturer's instructions. Briefly, cells
were harvested and resuspended in cell lysis buffer (108
cells/mL). After lysis, 106 cells were mixed with 32 μL of
assay buffer and 2 μL of 10 mM DEVD-pNA substrate.
Western blot analysis of NF-κB in RGC-5 cellsFigure 6
Western blot analysis of NF-κB in RGC-5 cells. Western blot analysis showing the effect of agmatine and BDNF on 
nuclear factor-kappa B (NF-κB). Western immunoblots probed with antibodies against NF-κB and phospho-NF-κB from 
nuclear (A) and cytosolic (B) proteins. Histone 3 (A) and β-actin (B) were used as internal controls.Page 8 of 11
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measured using a microplate reader at 405 nm. Absorb-
ance of each sample was determined by subtraction of the
mean absorbance of the blank from that of the sample.
Western blot analysis
For extraction of whole cellular proteins, cells were
washed twice with ice-cold phosphate buffered saline and
then lysed with cell lysis buffer (50 mM Tris-HCl pH 7.4,
1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA, 10 mM Na3VO4, 50 mM NaF, 1 mM PMSF, 1 μg/
mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin) on
ice for 30 minutes. Lysates were sonicated, and the cell
homogenates were centrifuged at 15,000 g for 10 minutes
(4°C).
For fractions of cytosolic and nuclear proteins, cells were
lysed with lysis buffer A (10 mM HEPES pH 7.4, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 10 mM
Na3VO4, 50 mM NaF, 1 mM PMSF, 1 μg/mL aprotinin, 1μg/mL leupeptin, 1 μg/mL pepstatin) on ice for 15 min-
utes, and 10% NP-40 was added. After vortexing for 10
seconds, lysates were centrifuged at 15,000 g for 1 minute
(4°C). Supernatant was collected from the cytosolic frac-
tion, and pellet was resuspended in lysis buffer C (20 mM
HEPES pH 7.4, 400 mM NaCl, 1 mM EDTA, 1% glycerol,
1 mM DTT, 10 mM Na3VO4, 50 mM NaF, 1 mM PMSF, 1μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin)
on ice for 30 minutes. Lysates were centrifuge at 15,000 g
for 15 minutes (4°C), and supernatant was collected from
the nuclear fraction.
Protein concentrations in the resultant supernatants were
determined with the Bradford reagent, and equal amounts
of protein (40 μg) were boiled in Laemmli sample buffer
and resolved by 10 or 15% SDS-PAGE. The proteins were
transferred to polyvinylidene fluoride membranes and
probed overnight with antibodies against JNK, ERK p44/
42, p38, NF-κB p65, phospho-JNK, phospho-ERK p44/42,
phospho-p38, phospho-NF-κB, β-actin and histone 3 as
indicated (diluted 1:1000). The immunoreactive bands
were detected with horseradish peroxidase-conjugated
secondary antibodies and visualized by enhanced chemi-
luminescence.
Statistical Analysis
Data were analyzed by a two-tailed Student t-test or a one-
way ANOVA using the Statistical Package for Social Sci-
ences 12.0 (SPSS). Differences were considered statisti-
cally significant at p < 0.05.
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